A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674
This study is recruiting at 45 US sites in 23 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Castration-resistant Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Amgen
- Last updated on ClinicalTrials.gov
- September 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 2
- City of Hope Cancer Center Phoenix · Goodyear, AZ
- University of Arizona Cancer Center · Tucson, AZ
California · 6
- City of Hope National Medical Center · Duarte, CA
- City of Hope Orange County Lennar Foundation Cancer Center · Duarte, CA
- Providence Saint Jude Medical Center · Fullerton, CA
- University of California Irvine · Orange, CA
- University of California San Francisco · San Francisco, CA
- Providence Saint Johns Health Center · Santa Monica, CA
Colorado · 1
- Rocky Mountain Cancer Centers · Denver, CO
Connecticut · 1
- Hartford HealthCare Cancer Institute at Hartford Hospital · Hartford, CT
Delaware · 1
- Medical Oncology Hematology Consultants Helen F Graham Cancer Center · Newark, DE
Florida · 1
- Moffitt Cancer Center · Tampa, FL
Georgia · 1
- City of Hope Atlanta · Newnan, GA
Illinois · 3
- University of Illinois Chicago · Chicago, IL
- Cancer Care Specialists of Illinois · Decatur, IL
- Midwestern Regional Medical Center dba City of Hope Chicago · Zion, IL
Kansas · 1
- University of Kansas Medical Center · Westwood, KS
Kentucky · 2
- Norton Cancer Institute · Louisville, KY
- University of Louisville Health - James Graham Brown Cancer Center · Louisville, KY
Maryland · 2
- Johns Hopkins Hospital Sidney Kimmell Comprehensive Cancer Center · Baltimore, MD
- University of Maryland Greenebaum Cancer Center · Baltimore, MD
Michigan · 1
- Barbara Ann Karmanos Cancer Institute · Lansing, MI
Minnesota · 2
- Minnesota Oncology Hematology PA · Minneapolis, MN
- University of Minnesota Medical Center Fairview · Minneapolis, MN
New York · 2
- Hematology Oncology Association of Central New York · East Syracuse, NY
- Memorial Sloan Kettering Cancer Center · New York, NY
Ohio · 3
- Oncology Hematology Care Incorporated · Cincinnati, OH
- The Ohio State University · Columbus, OH
- Dayton Physicians LLC Dayton · Dayton, OH
Oklahoma · 1
- Hightower Clinical · Oklahoma City, OK
Oregon · 1
- Oregon Oncology Specialists · Salem, OR
Pennsylvania · 1
- University of Pittsburgh Medical Center · Pittsburgh, PA
South Carolina · 1
- South Texas Accelerated Research Therapeutics - Carolinas · Myrtle Beach, SC
Tennessee · 2
- Sarah Cannon Research Institute Oncology Partners · Nashville, TN
- United States Oncology Regulatory Affairs Corporate Office · Nashville, TN
Texas · 5
- The Center for Cancer and Blood Disorders · Arlington, TX
- University of Texas Southwestern Medical Center · Dallas, TX
- Renovatio Clinical · Houston, TX
- Texas Oncology - Northeast Texas · Tyler, TX
- US Oncology Research Investigational Products Center · Tyler, TX
Virginia · 4
- University of Virginia Cancer Center · Charlottesville, VA
- Virginia Cancer Specialists PC · Leesburg, VA
- Bon Secours Cancer Institute at Saint Francis · Midlothian, VA
- Virginia Oncology Associates · Norfolk, VA
Washington · 1
- Northwest Medical Specialties, PLLC · Tacoma, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.